Overview
November 04, 2026
Bad Homburg, Germany
Conference Call Q3 2026
The webcast with senior management will take place at 1:30 p.m. CET.
Fresenius delivered another excellent quarter, underscoring the strength and consistency of our execution. […] This performance enables us to improve our Core EPS outlook and raise our Group EBIT margin indication. Our strategy is translating into measurable results. Kabi’s Growth Vectors delivered 9% organic growth, led by Biopharma at 29%, while Helios achieved strong growth and margin expansion. We are progressing #FutureFresenius with disciplined investments, including the acquisition of the remaining 45% of mAbxience and our strategic agreement with WuXi Biologics, which will significantly expand and accelerate our biosimilars pipeline. […]”
Michael Sen, CEO Fresenius
Financial Results
Q3/2026: Fresenius delivers an excellent quarter and is scaling its Growth Vectors.
Outlook
Group FY/26 Core EPS guidance improved: Fresenius outlook at a glance.
Financial Reports
Discover Fresenius financial reports and presentations here!
Goals & Strategy
Our strategy is translating into measurable results. Find out more about our company’s strategy!
Financial Highlights Q3/2026
Group Revenue 1
€ 5803 m
+5% 1, 2
Q3/25: €5,477 m
Group EBIT 1
€ 638 m
+10% 4
Q3/25: €574 m
Core Net income 1, 3
€ 403 m
+14% 4
Q3/25: €351 m
Core EPS 1, 3
€ 0.72
+14% 4
Q3/25: €0.62
KABI Revenue 1
€ 2304 m
+6% 2
Q3/25: €2,141 m
HELIOS Revenue 1
€ 3405 m
+5% 2
Q3/25: €3,240 m
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Excluding Fresenius Medical Care and Vitrea
4 Constant currency growth
Letter to our shareholders
Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. Read the full CEO-letter!
Sustainability Statement
Our Sustainability Statement shows how we address environmental, social, and governance topics and manage the associated impacts, risks, and opportunities. Read more here!
Strategy and goals
Our vision is to be the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level therapies. Read more about our corporate strategy!
Rejuvenate
In 2025, Fresenius entered the next phase of our #FutureFresenius strategy: Rejuvenate. We have defined three priorities that guide our actions across the entire company. Discover more in the stories.
Investor Feedback
Open dialogue is valuable for us.
You can submit your feedback quickly and easily using the link below (anonymously if you prefer).
You will be redirected to QuantiFire which conducts this survey in own controllership.
News
-
Fresenius delivers an excellent quarter and is scaling its Growth Vectors - Core EPS guidance improved
![]()
Fresenius delivers an excellent quarter and is scaling its Growth Vectors - Core EPS guidance improved
Michael Sen, CEO of Fresenius: “Fresenius delivered another excellent quarter, underscoring the strength and consistency of our execution. This performance enables us to improve our Core EPS outlook and raise our Group EBIT margin indication.
November 04, 2026 · Fresenius
-
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
![]()
Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline
Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced that it has entered an exclusive development agreement with WuXi Biologics (2269.HK), a leading global contract organization for research, development and manufacturing. WuXi Biologics brings proven large-scale biologics development and manufacturing capability, a track record across monoclonal and bispecific antibodies and antibody-drug conjugates, and a worldwide network spanning Europe, the United States, China and Singapore.
November 02, 2026 · Fresenius Kabi
-
Brief News
Q3 2026 Aide Memoire available
Fresenius announced today that the Company's Q3 2026 Aide Memoire is now available on the Company's Investor Relations overview section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q3 2026 financial results will be published on November 4, 2026.
October 13, 2026 · Fresenius
-
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
![]()
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
NutriChef launches in several European markets and combines real food ingredients1 with the consistency and nutritional completeness of medical nutritionThe launch of NutriChef, the fifth product launch within Fresenius’ Medical Nutrition portfolio in 2026, reflects the company’s commitment to patient-centered innovation-led growth and further strengthens its portfolio in nutritional careNutriChef expands Fresenius’ enteral nutrition offering with a real-food-based concept designed around the needs of patients, caregivers, and healthcare professionalsMedical Nutrition is an attractive healthcare market supported by aging populations, increased demand for homecare, and growing awareness of the role of nutrition in patient careFresenius announced today the launch of NutriChef, a new enteral nutrition option that combines real food ingredients1 such as fruit and vegetables while maintaining the nutritional completeness required for medical nutrition, in Germany, Switzerland, Norway, Netherlands, Denmark, and Sweden.The product is designed to bridge the gap between conventional formula-based tube feeding and the familiarity associated with real meals and home-prepared foods. Available in three nutritionally complete, meal-inspired varieties2, they contain ingredients derived from 21 different plants and more than 75 percent real food ingredients, including water and oils1. The product provides high energy and protein as well as a blend of soluble and insoluble fibers.“For many patients, the challenge is not only getting the nutrition they need. It is adapting to a new reality,” said Sebastien Guery, Executive Vice President Business Unit Medical Nutrition. “NutriChef responds to that need by combining familiar foods into enteral feeding with the safety, consistency and nutritional standards required in medical care. It is also a testament to the innovation-led growth of Fresenius, reflecting our ability to translate evolving patient needs into differentiated innovations and meaningful portfolio expansion.”Developed for patients who require enteral nutrition, the new offering combines familiar food-based ingredients with the reliability and quality standards expected from medical nutrition. It offers patients, caregivers, and healthcare professionals an additional option that brings familiar food concepts into nutritional care.As populations age and more care shifts beyond the hospital into outpatient and homecare settings, nutritional support is becoming increasingly important across healthcare systems. Fresenius continues to see strong long-term demand in Medical Nutrition, supported by demographic trends, growing awareness of disease-related malnutrition, and the need for solutions that fit into patients’ daily lives.As the fifth addition to Fresenius’ Medical Nutrition portfolio introduced in 2026, NutriChef underscores the company’s continued investment in nutritional care across enteral and parenteral nutrition, the company continues to expand access to high-quality medical nutrition while addressing practical challenges faced by patients, caregivers, and healthcare professionals. As part of #FutureFresenius, the company continues to strengthen its portfolio with differentiated solutions that address evolving patient needs.NutriChef is a food for special medical purposes for the dietary management of disease-related malnutrition, to be used under medical supervision. Product availability may vary by market.NutriChef is essentially designed as an adult medical nutrition product, with limited, controlled use in:children >3 years (restricted)adolescents (possible full use only with medical supervision)References1 Fresenius Kabi. NutriChef Ingredient List and Product Specification. Fresenius Kabi; 2026.2 Fresenius Kabi Market Research; Real Food & Tube Feeding Insights Study, 2022.
September 07, 2026 · Fresenius Kabi
-
Brief News
Q2 2026 Aide Memoire available
Fresenius announced today that the Company's Q2 2026 Aide Memoire is now available on the Company's financial results section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.
July 15, 2026 · Fresenius
Stay Connected with Fresenius Investor Relations on LinkedIn
Follow Fresenius Investor Relations for expert insights and latest news that contribute to the Fresenius equity story, and exclusive content from our team. Join our growing community and be part of the conversation!
